vs
Side-by-side financial comparison of EVERSPIN TECHNOLOGIES INC. (MRAM) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $14.9M, roughly 1.4× EVERSPIN TECHNOLOGIES INC.). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -20.4%, a 18.4% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs 6.9%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs 2.9%).
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
MRAM vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.9M | $20.4M |
| Net Profit | $-296.0K | $-4.2M |
| Gross Margin | 52.7% | 87.3% |
| Operating Margin | 29.0% | -18.0% |
| Net Margin | -2.0% | -20.4% |
| Revenue YoY | 13.2% | 6.9% |
| Net Profit YoY | — | 64.9% |
| EPS (diluted) | $-0.01 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.9M | — | ||
| Q4 25 | $14.8M | $20.4M | ||
| Q3 25 | $14.1M | $19.9M | ||
| Q2 25 | $13.2M | $19.6M | ||
| Q1 25 | $13.1M | $17.5M | ||
| Q4 24 | $13.2M | $19.1M | ||
| Q3 24 | $12.1M | $20.2M | ||
| Q2 24 | $10.6M | $21.4M |
| Q1 26 | $-296.0K | — | ||
| Q4 25 | $1.2M | $-4.2M | ||
| Q3 25 | $54.0K | $-8.2M | ||
| Q2 25 | $-670.0K | $-11.9M | ||
| Q1 25 | $-1.2M | $-14.2M | ||
| Q4 24 | $1.2M | $-11.8M | ||
| Q3 24 | $2.3M | $-11.1M | ||
| Q2 24 | $-2.5M | $-12.3M |
| Q1 26 | 52.7% | — | ||
| Q4 25 | 50.8% | 87.3% | ||
| Q3 25 | 51.3% | 86.4% | ||
| Q2 25 | 51.3% | 84.8% | ||
| Q1 25 | 51.4% | 86.2% | ||
| Q4 24 | 51.3% | 86.8% | ||
| Q3 24 | 49.2% | 83.9% | ||
| Q2 24 | 49.0% | 85.8% |
| Q1 26 | 29.0% | — | ||
| Q4 25 | -7.2% | -18.0% | ||
| Q3 25 | -11.0% | -39.7% | ||
| Q2 25 | -14.9% | -59.6% | ||
| Q1 25 | -14.7% | -79.2% | ||
| Q4 24 | -11.8% | -62.5% | ||
| Q3 24 | -17.5% | -55.7% | ||
| Q2 24 | -26.5% | -59.2% |
| Q1 26 | -2.0% | — | ||
| Q4 25 | 8.1% | -20.4% | ||
| Q3 25 | 0.4% | -41.0% | ||
| Q2 25 | -5.1% | -61.0% | ||
| Q1 25 | -8.9% | -80.8% | ||
| Q4 24 | 9.2% | -62.1% | ||
| Q3 24 | 18.8% | -54.9% | ||
| Q2 24 | -23.5% | -57.7% |
| Q1 26 | $-0.01 | — | ||
| Q4 25 | $0.05 | $-0.07 | ||
| Q3 25 | $0.00 | $-0.16 | ||
| Q2 25 | $-0.03 | $-0.23 | ||
| Q1 25 | $-0.05 | $-0.28 | ||
| Q4 24 | $0.07 | $-0.23 | ||
| Q3 24 | $0.10 | $-0.22 | ||
| Q2 24 | $-0.12 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.5M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $70.2M | $63.9M |
| Total Assets | $83.2M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.5M | — | ||
| Q4 25 | $44.5M | $92.0M | ||
| Q3 25 | $45.3M | $92.4M | ||
| Q2 25 | $45.0M | $101.5M | ||
| Q1 25 | $42.2M | $108.8M | ||
| Q4 24 | $42.1M | $120.4M | ||
| Q3 24 | $39.6M | $118.6M | ||
| Q2 24 | $36.8M | $118.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M |
| Q1 26 | $70.2M | — | ||
| Q4 25 | $68.9M | $63.9M | ||
| Q3 25 | $65.8M | $64.3M | ||
| Q2 25 | $64.1M | $70.0M | ||
| Q1 25 | $63.0M | $77.6M | ||
| Q4 24 | $62.6M | $87.5M | ||
| Q3 24 | $59.3M | $95.0M | ||
| Q2 24 | $55.4M | $101.6M |
| Q1 26 | $83.2M | — | ||
| Q4 25 | $84.6M | $115.3M | ||
| Q3 25 | $80.3M | $116.3M | ||
| Q2 25 | $78.9M | $122.0M | ||
| Q1 25 | $80.2M | $129.7M | ||
| Q4 24 | $77.8M | $142.8M | ||
| Q3 24 | $72.6M | $143.6M | ||
| Q2 24 | $64.6M | $149.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $570.0K | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $570.0K | — | ||
| Q4 25 | $2.6M | $-1.8M | ||
| Q3 25 | $881.0K | $-8.7M | ||
| Q2 25 | $5.0M | $-7.5M | ||
| Q1 25 | $1.4M | $-11.6M | ||
| Q4 24 | $3.8M | $-3.5M | ||
| Q3 24 | $2.8M | $362.0K | ||
| Q2 24 | $1.7M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-975.0K | $-2.0M | ||
| Q3 25 | $543.0K | $-8.9M | ||
| Q2 25 | $3.0M | $-7.8M | ||
| Q1 25 | $527.0K | — | ||
| Q4 24 | $2.1M | $-3.6M | ||
| Q3 24 | $2.8M | $311.0K | ||
| Q2 24 | $1.7M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | -6.6% | -9.7% | ||
| Q3 25 | 3.9% | -44.7% | ||
| Q2 25 | 22.9% | -39.6% | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 15.8% | -18.9% | ||
| Q3 24 | 22.9% | 1.5% | ||
| Q2 24 | 15.9% | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | 24.3% | 0.8% | ||
| Q3 25 | 2.4% | 0.9% | ||
| Q2 25 | 15.1% | 1.1% | ||
| Q1 25 | 6.9% | 0.0% | ||
| Q4 24 | 13.2% | 0.7% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 0.3% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.19× | — | ||
| Q3 25 | 16.31× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.16× | — | ||
| Q3 24 | 1.25× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
